Domainex expands executive team to support ongoing growth
Saffron Walden, UK, 21st January 2021 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to welcome David Cronk, CBiol, MRSB, to the team as its new Chief of Staff. The Company has also promoted long standing team member and previous Head of Chemistry, Dr Ray Boffey, to Executive Director of Medicines Research. Following a successful period of growth and expansion of its research team, both David and Ray bring a wealth of drug discovery experience and will further support Domainex’s ongoing growth plans.
David Cronk has over 30 years’ drug discovery experience in CRO, large pharma and biotech companies. He joins Domainex after 15 years at Charles River Laboratories as Science Director where he specialised in High Throughput Screening Sciences and worked closely with a range of globally distributed client organisations to deliver HTS projects using cellular and biochemical assay formats, including screening using high throughput mass spectrometry. In this arena, David has worked on a diverse collection of targets, including GPCRs, ion channels, transporters, protein-protein interactions and enzymes.
David also has a keen interest in compound management and technologies applicable to in vitro biological assays which support hit finding and downstream chemical optimisation. As Chief of Staff, David will focus on strengthening Domainex’s existing capabilities and will further enhance these through investment and establishing collaborations with partner organisations.
Dr Ray Boffey has been with Domainex since 2010 and has over 20 years of drug discovery experience in CRO and biotech companies. Over his career, Ray has directed programmes from hit identification through to candidate nomination, tackling a wide range of biological targets including protein-protein interactions, ion-channels, GPCRs, enzymes and integrins. These programmes cover therapeutic areas such as oncology, inflammation and Parkinson’s disease.
In his new position as Executive Director of Medicines Research, Ray will help to guide Domainex’s drug discovery programmes, with the aim of progressing more client projects towards the clinic and ultimately aiming to help more patients with life altering conditions.
Dr Tom Mander, CEO of Domainex, commented, “I am thrilled to welcome David to the team. His wealth of experience in drug discovery makes him the ideal candidate to help guide Domainex during this exciting period of growth. We are also pleased to recognise the talent of the highly experienced Domainex team and Ray’s contributions to the success of the Company over the last decade. These additions to our executive team will further strengthen Domainex’s management and help to drive our innovative research.”
David Cronk added, “I am excited to join the Domainex team at such an interesting time for the Company and am impressed with the scientific strength and depth within the organisation. I look forward to building on its success so far and drawing on my experience to enhance Domainex’s unique drug discovery offerings.”
Ray Boffey commented, “Having worked on many exciting research projects with Domainex over the last 10 years, I am delighted to take on this new role and with our highly skilled and committed team help to expand the vital work we do to advance our partners’ medicines pipelines.”
For more information, contact:
Dr. Tom Mander, CEO
Media Relations – Sciad Communications
Deborah Cockerill / Juliette Craggs / Katie Warren
T: +44 (0)20 3405 7892
Notes to editors
About Domainex Ltd.
Domainex is a leading integrated medicines research service partner working with ambitious life science organisations from around the globe. We have been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions.
We provide innovative and customised assay and structural biology and computational, synthetic, medicinal and analytical chemistry services to advance the disease research projects of our partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression for our partners’ research and our approach consistently saves up to 30% of the time needed to discover new medicines by comparison with the industry average. Our innovative science and extensive technical capabilities enable us to produce novel medicines to treat diseases with strong commercial potential. We work closely and collaboratively with our customers to understand their aspirations, bringing our ideas, know-how and wealth of experience to bear on their projects.
Our highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges including being named on over 60 patent applications and the invention of numerous candidate drugs. We aim to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.
Full information about Domainex and our award-winning services can be found at www.domainex.co.uk.